AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
Log in

NASDAQ:MBIIMarrone Bio Innovations Stock Price, Forecast & News

$1.00
-0.01 (-0.99 %)
(As of 06/2/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.00
Now: $1.00
$1.04
50-Day Range
$0.63
MA: $0.88
$1.10
52-Week Range
$0.61
Now: $1.00
$1.73
Volume93,934 shs
Average Volume213,961 shs
Market Capitalization$145.53 million
P/E RatioN/A
Dividend YieldN/A
Beta0.28
Marrone Bio Innovations, Inc. provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation. The company's products include Regalia, a plant extract-based fungicidal biopesticide for plant disease and plant health; and Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants. It also provides Zequanox, a biomolluscicide that controls invasive mussels, which cause infrastructure and ecological damage primarily to power and industrial companies; and Venerate, a bioinsecticide, which controls chewing and sucking insects and mites, as well as flies and plant parasitic nematodes. In addition, the company offers Stargus/Amplitude, a biofungicide to control plant diseases, such as Sclerotinia white molds, gray mold/bunch rot, and downy mildews; Haven, a plant health product that is applied to the leaves of plants to reduce sun stress; and Majestene and Zelto, a bionematicide to control soil-dwelling nematodes by preventing and reducing root galls, as well as reducing adult reproduction and egg hatch. Marrone Bio Innovations, Inc. provides its products directly through sales force, as well as through distributors. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was founded in 2006 and is headquartered in Davis, California.
Read More
Marrone Bio Innovations logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars


Industry, Sector and Symbol

Industry Agricultural chemicals
Sub-IndustryN/A
SectorBasic Materials
Current SymbolNASDAQ:MBII
CUSIPN/A
Phone530-750-2800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$29.37 million
Book Value$0.18 per share

Profitability

Net Income$-37,170,000.00
Net Margins-132.76%

Miscellaneous

Employees113
Market Cap$145.53 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive MBII News and Ratings via Email

Sign-up to receive the latest news and ratings for MBII and its competitors with MarketBeat's FREE daily newsletter.

Marrone Bio Innovations (NASDAQ:MBII) Frequently Asked Questions

How has Marrone Bio Innovations' stock been impacted by COVID-19 (Coronavirus)?

Marrone Bio Innovations' stock was trading at $0.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MBII shares have increased by 16.3% and is now trading at $1.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Marrone Bio Innovations?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marrone Bio Innovations in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Marrone Bio Innovations.

When is Marrone Bio Innovations' next earnings date?

Marrone Bio Innovations is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Marrone Bio Innovations.

How were Marrone Bio Innovations' earnings last quarter?

Marrone Bio Innovations Inc (NASDAQ:MBII) posted its earnings results on Monday, May, 11th. The basic materials company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01. The basic materials company had revenue of $9.65 million for the quarter, compared to the consensus estimate of $9.78 million. Marrone Bio Innovations had a negative net margin of 132.76% and a negative return on equity of 136.82%. View Marrone Bio Innovations' earnings history.

What price target have analysts set for MBII?

3 brokerages have issued twelve-month target prices for Marrone Bio Innovations' shares. Their forecasts range from $1.40 to $2.50. On average, they expect Marrone Bio Innovations' stock price to reach $1.88 in the next year. This suggests a possible upside of 88.3% from the stock's current price. View analysts' price targets for Marrone Bio Innovations.

What are Wall Street analysts saying about Marrone Bio Innovations stock?

Here are some recent quotes from research analysts about Marrone Bio Innovations stock:
  • 1. HC Wainwright analysts commented, "We have not yet incorporated the effect of the financing and the proposed acquisition in our model. If, and when, the transaction closes, we believe that the company’s revenues for 2019 should be expected to be higher, relative to our current expectation, by single-digit millions. Currently, we are projecting MBII to generate revenues of $30.3M in 2019. We expect revenues to reach $160.7M in 2025, growing at a six-year CAGR of 32.0%, relative to 2019 levels. We are estimating gross margin to stay at 55-56% level for the next several years." (8/12/2019)
  • 2. National Securities analysts commented, "Second Quarter Results. Revenue of $7.0 million grew 22% YoY but missed consensus estimates of $8.3 million, while gross margins improved and adjusted operating expenses remained roughly flat sequentially. Overall, the second quarter continued the trend of directional improvement, but the scale of the improvement was a modest disappointment to us especially when considering what were favorable comps off of a weak second quarter of 2018.
     Acquisition Of Pro Farm The Highlight. Most significantly, MBII announced its acquisition of a biostimulant peer Pro Farm Technologies for $31.8 million. The acquisition expands MBII’s presence in the high growth seed treatment market and diversifies its product offering away from biopesticides with a second biostimulant offering.
     Supportive Of The Transaction. We are bullish on the seed treatment market over both the near and long term and believe additional exposure can create meaningful shareholder value. Furthermore, given our estimates for the financial impact, the acquisition enhances our belief that MBII will pivot to cash flow breakeven in 2021. We had previously modeled MBII to operate at Adjusted EBITDA breakeven in 2021. With the transaction, we look for 2021 to now generate a modest EBITDA profit.
     Long Term Value Creation. With the integration of Pro Farms and collaborations with other commercial partners, MBII is targeting a more diverse product portfolio that broadens its biological offerings beyond biopesticides to include biostimulants and biofertilizers. Should scale develop as we believe it can over the mid-term, we believe MBII will look increasingly attractive to larger peers which may generate meaningful value for long term shareholders." (8/9/2019)
  • 3. Aegis analysts commented, "We think Marrone Bio has a scalable, repeatable business model. We think Marrone Bio’s roots are in innovation, with an organization that is heavy on research talent, with a tenured management team of industry veterans. In recent years, Marrone’s focus has been on commercializing this R&D investment, and the company has a portfolio of commercial products on the market. Marrone Bio’s model consists of discovering novel bio-based compounds, refining them with in-house expertise and laboratory equipment, and introducing them to the commercial sphere. We think Marrone can continue to execute on this strategy as it moves increasingly close to profitability." (7/24/2019)

Has Marrone Bio Innovations been receiving favorable news coverage?

Media stories about MBII stock have trended somewhat negative this week, InfoTrie reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Marrone Bio Innovations earned a daily sentiment score of -1.6 on InfoTrie's scale. They also gave news headlines about the basic materials company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutMarrone Bio Innovations.

Are investors shorting Marrone Bio Innovations?

Marrone Bio Innovations saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 3,210,000 shares, an increase of 7.4% from the April 30th total of 2,990,000 shares. Based on an average daily volume of 228,600 shares, the short-interest ratio is currently 14.0 days. Approximately 3.7% of the company's shares are sold short. View Marrone Bio Innovations' Current Options Chain.

Who are some of Marrone Bio Innovations' key competitors?

What other stocks do shareholders of Marrone Bio Innovations own?

Who are Marrone Bio Innovations' key executives?

Marrone Bio Innovations' management team includes the following people:
  • Dr. Pamela G. Marrone, Founder, CEO & Director (Age 62)
  • Mr. James B. Boyd, Pres & CFO (Age 66)
  • Ms. Linda V. Moore, Chief Compliance Officer, Gen. Counsel, Exec. VP & Sec. (Age 72)
  • Dr. Amit Vasavada Ph.D., Sr. VP of R&D and CTO (Age 64)
  • Andre Trepanier, Director of Marketing

What is Marrone Bio Innovations' stock symbol?

Marrone Bio Innovations trades on the NASDAQ under the ticker symbol "MBII."

Who are Marrone Bio Innovations' major shareholders?

Marrone Bio Innovations' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.81%), Primecap Management Co. CA (1.55%), State Street Corp (0.57%), Geode Capital Management LLC (0.41%), Essex Investment Management Co. LLC (0.28%) and Rhumbline Advisers (0.07%). Company insiders that own Marrone Bio Innovations stock include Ardsley Advisory Partners and Van Herk Investments BV. View institutional ownership trends for Marrone Bio Innovations.

Which major investors are selling Marrone Bio Innovations stock?

MBII stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Primecap Management Co. CA, BlackRock Inc., UBS Group AG, and Spark Investment Management LLC. View insider buying and selling activity for Marrone Bio Innovations.

Which major investors are buying Marrone Bio Innovations stock?

MBII stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Rhumbline Advisers, JPMorgan Chase & Co., and State Street Corp. View insider buying and selling activity for Marrone Bio Innovations.

How do I buy shares of Marrone Bio Innovations?

Shares of MBII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Marrone Bio Innovations' stock price today?

One share of MBII stock can currently be purchased for approximately $1.00.

How big of a company is Marrone Bio Innovations?

Marrone Bio Innovations has a market capitalization of $145.53 million and generates $29.37 million in revenue each year. The basic materials company earns $-37,170,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Marrone Bio Innovations employs 113 workers across the globe.

What is Marrone Bio Innovations' official website?

The official website for Marrone Bio Innovations is www.marronebioinnovations.com.

How can I contact Marrone Bio Innovations?

Marrone Bio Innovations' mailing address is 1540 Drew Avenue, Davis CA, 95618. The basic materials company can be reached via phone at 530-750-2800 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.